Provided by Tiger Trade Technology Pte. Ltd.

Exelixis

57.43
-0.9000-1.54%
Post-market: 57.430.00000.00%18:38 EDT
Volume:1.79M
Turnover:103.03M
Market Cap:14.23B
PE:18.06
High:58.33
Open:58.33
Low:57.23
Close:58.33
52wk High:59.72
52wk Low:33.76
Shares:247.78M
Float Shares:214.00M
Volume Ratio:0.82
T/O Rate:0.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.18
EPS(LYR):2.78
ROE:44.39%
ROA:23.97%
PB:7.72
PE(LYR):20.66

Loading ...

Exelixis Posts Strong Q1 Results, Expands Share Buybacks

TIPRANKS
·
May 06

Exelixis Q1 revenue slightly beats estimates

Reuters
·
May 06

GUIDANCE: (EXEL) Exelixis Expects Full Year 2026 Revenue Range $2.53B - $2.63B, vs. FactSet Est of $2.58B

MT Newswires Live
·
May 06

Exelixis Q1 FY26 GAAP diluted EPS climbs to $0.79; revenue rises to $610.8 million

Reuters
·
May 06

Exelixis Q1 Adj. EPS $0.87 Beats $0.70 Estimate, Sales $610.812M Beat $605.196M Estimate

Benzinga Earnings
·
May 06

BRIEF-Exelixis Q1 Revenue USD 610.8 Million Vs. IBES Estimate USD 605.2 Million

Reuters
·
May 06

Exelixis Guidance 2026 Total Revenues $2.525 Billion - $2.625 Billion

THOMSON REUTERS
·
May 06

Exelixis Inc - Maintains 2026 Financial Guidance

THOMSON REUTERS
·
May 06

Exelixis Inc - in May, Board Authorizes $750 Mln Stock Repurchase Program in May 2026

THOMSON REUTERS
·
May 06

Exelixis Inc - Initiates Stellar-201 Phase 2 Trial of Zanzalintinib in Recurrent Meningioma

THOMSON REUTERS
·
May 06

Earning Preview: Exelixis Q1 revenue is expected to increase by 21.51%, and institutional views are cautious with Hold calls dominant

Earnings Agent
·
Apr 28

Exelixis and Merck Advance Key Phase 3 Kidney Cancer Trial, Setting Up a New Catalyst for EXEL

TIPRANKS
·
Apr 24

Does Exelixis (EXEL) Gain Quiet Competitive Leverage From a Rival’s Kidney Cancer Setback?

Simply Wall St.
·
Apr 23

The Tactical Trio Blueprint For Solid Balance Sheet And Fundamentals

Simply Wall St.
·
Apr 22

Exelixis schedules quarterly results release and conference call

Reuters
·
Apr 22

Exelixis Is Maintained at Equal-Weight by Barclays

Dow Jones
·
Apr 20

A Look At Exelixis (EXEL) Valuation As CABOMETYX Growth And Trial Outlook Shape Expectations

Simply Wall St.
·
Apr 17

Exelixis publishes 2025 annual report

Reuters
·
Apr 16

Exelixis announces annual shareholder meeting

Reuters
·
Apr 16

Wells Fargo Sticks to Its Hold Rating for Exelixis (EXEL)

TIPRANKS
·
Apr 14